专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

1. 发明申请

US20070191604A1 Novel compounds that are ERK inhibitors 审中-公开
标题翻译： ERK抑制剂的新型化合物
公开(公告)号：US20070191604A1
公开(公告)日：2007-08-16
申请号：US11636954
申请日：2006-12-11
申请人： Alan Cooper , Yongqi Deng , Gerald Shipps , Neng-Yang Shih , Hugh Zhu , Robert Sun , Joseph Kelly , Ronald Doll , Yang Nan , Tong Wang , Jagdish Desai , James Wang , Youhao Dong , Vincent Madison , Li Xiao , Alan Hruza , M. Siddiqui , Ahmed Samatar , Sunil Paliwal , Hon-Chung Tsui , Azim Celebi , Yiji Wu , Sobhana Boga
发明人： Alan Cooper , Yongqi Deng , Gerald Shipps , Neng-Yang Shih , Hugh Zhu , Robert Sun , Joseph Kelly , Ronald Doll , Yang Nan , Tong Wang , Jagdish Desai , James Wang , Youhao Dong , Vincent Madison , Li Xiao , Alan Hruza , M. Siddiqui , Ahmed Samatar , Sunil Paliwal , Hon-Chung Tsui , Azim Celebi , Yiji Wu , Sobhana Boga
IPC分类号： C07D417/14 , C07D413/14 , C07D403/14
CPC分类号： C07D405/14 , C07D231/56 , C07D401/14 , C07D403/12 , C07D403/14 , C07D409/12 , C07D409/14 , C07D413/12 , C07D417/14
摘要： Disclosed are the ERK inhibitors of formula 1.0: and the pharmaceutically acceptable salts and solvates thereof. Q is a piperidine or piperazine ring that can have a bridge or a fused ring. The piperidine ring can have a double bond in the ring. All other substitutents are as defined herein. Also disclosed are methods of treating cancer using the compounds of formula 1.0.
摘要翻译：公开了式1.0的ERK抑制剂及其药学上可接受的盐和溶剂化物。 Q是可以具有桥或稠合环的哌啶或哌嗪环。哌啶环可以在环中具有双键。所有其他取代基如本文所定义。还公开了使用式1.0化合物治疗癌症的方法。

2. 发明申请

US20070232610A1 Novel compounds that are ERK inhibitors 失效
公开(公告)号：US20070232610A1
公开(公告)日：2007-10-04
申请号：US11705709
申请日：2007-02-13
申请人： Yongqi Deng , Gerald Shipps , Alan Cooper , Yang Nan , Tong Wang , M. Siddiqui , Hugh Zhu , Robert Sun , Joseph Kelly , Ronald Doll , Jagdish Desai , James Wang , Youhao Dong , Vincent Madison , Li Xiao , Alan Hruza , Neng-Yang Shih
发明人： Yongqi Deng , Gerald Shipps , Alan Cooper , Yang Nan , Tong Wang , M. Siddiqui , Hugh Zhu , Robert Sun , Joseph Kelly , Ronald Doll , Jagdish Desai , James Wang , Youhao Dong , Vincent Madison , Li Xiao , Alan Hruza , Neng-Yang Shih
IPC分类号： A61K31/53 , A61K31/506 , A61K31/502 , A61K31/497 , A61K31/4439 , A61K31/407 , A61K31/401 , C07D403/02
CPC分类号： C07D207/16 , C07D401/06 , C07D401/12 , C07D401/14 , C07D403/06 , C07D403/12 , C07D405/12 , C07D405/14 , C07D409/12 , C07D413/12 , C07D413/14 , C07D417/12 , C07D417/14 , C07D487/08
摘要： Disclosed are the ERK inhibitors of formula 1.0: and the pharmaceutically acceptable salts and solvates thereof. Q is a piperidine or piperazine ring that can have a bridge or a fused ring. The piperidine ring can have a double bond in the ring. All other substitutents are as defined herein. Also disclosed are methods of treating cancer using the compounds of formula 1.0.

3. 发明授权

US07807672B2 Compounds that are ERK inhibitors 失效
标题翻译： ERK抑制剂的化合物
公开(公告)号：US07807672B2
公开(公告)日：2010-10-05
申请号：US11705709
申请日：2007-02-13
申请人： Yongqi Deng , Gerald W. Shipps, Jr. , Alan Cooper , Yang Nan , Tong Wang , M. Arshad Siddiqui , Hugh Zhu , Robert Sun , Joseph M. Kelly , Ronald Doll , Jagdish Desai , James J-S Wang , Youhao Dong , Vincent Madison , Li Xiao , Alan Hruza , Neng-Yang Shih
发明人： Yongqi Deng , Gerald W. Shipps, Jr. , Alan Cooper , Yang Nan , Tong Wang , M. Arshad Siddiqui , Hugh Zhu , Robert Sun , Joseph M. Kelly , Ronald Doll , Jagdish Desai , James J-S Wang , Youhao Dong , Vincent Madison , Li Xiao , Alan Hruza , Neng-Yang Shih
IPC分类号： A61K31/506 , A61K31/5377 , A61K31/4025 , A61K31/496 , C07D401/06 , C07D401/12 , C07D401/14 , C07D403/12 , C07D405/12 , C07D413/12 , C07D417/06 , C07D417/12
CPC分类号： C07D207/16 , C07D401/06 , C07D401/12 , C07D401/14 , C07D403/06 , C07D403/12 , C07D405/12 , C07D405/14 , C07D409/12 , C07D413/12 , C07D413/14 , C07D417/12 , C07D417/14 , C07D487/08
摘要： Disclosed are the ERK inhibitors of formula 1.0: and the pharmaceutically acceptable salts and solvates thereof. Q is a piperidine or piperazine ring that can have a bridge or a fused ring. The piperidine ring can have a double bond in the ring. All other substituents are as defined herein. Also disclosed are methods of treating cancer using the compounds of formula 1.0.
摘要翻译：公开了式1.0的ERK抑制剂及其药学上可接受的盐和溶剂化物。 Q是可以具有桥或稠合环的哌啶或哌嗪环。哌啶环可以在环中具有双键。所有其它取代基如本文所定义。还公开了使用式1.0化合物治疗癌症的方法。

4. 发明申请

US20090118284A1 Novel compounds that are ERK inhibitors 有权
标题翻译： ERK抑制剂的新型化合物
公开(公告)号：US20090118284A1
公开(公告)日：2009-05-07
申请号：US11810282
申请日：2007-06-05
申请人： Alan B. Cooper , Yongqi Deng , Gerald W. Shipps, JR. , Neng-Yang Shih , Hugh Y. Zhu , Robert Sun , Joseph M. Kelly , Ronald J. Doll , Yang Nan , Tong Wang , Jagdish A. Desai , James J-S Wang , Youhao Dong , Vincent S. Madison , Li Xiao , Alan W. Hruza , M. Arshad Siddiqui , Ahmed A. Samatar , Sunil Paliwal , Hon-Chung Tsui , Azim Alan Celebi , Yiji Wu , Sobhana Babu Boga , Abdul-Basit Alhassan , Xiaolei Gao , Liang Zhu , Mehul Patel
发明人： Alan B. Cooper , Yongqi Deng , Gerald W. Shipps, JR. , Neng-Yang Shih , Hugh Y. Zhu , Robert Sun , Joseph M. Kelly , Ronald J. Doll , Yang Nan , Tong Wang , Jagdish A. Desai , James J-S Wang , Youhao Dong , Vincent S. Madison , Li Xiao , Alan W. Hruza , M. Arshad Siddiqui , Ahmed A. Samatar , Sunil Paliwal , Hon-Chung Tsui , Azim Alan Celebi , Yiji Wu , Sobhana Babu Boga , Abdul-Basit Alhassan , Xiaolei Gao , Liang Zhu , Mehul Patel
IPC分类号： A61K31/496 , C07D403/14 , C07D413/14 , A61K31/506 , A61P35/00 , A61P35/02 , A61K31/4439 , A61K31/5377 , C07D401/14
CPC分类号： C07D231/56 , C07D401/14 , C07D403/12 , C07D403/14 , C07D405/14 , C07D409/12 , C07D409/14 , C07D413/12 , C07D417/14
摘要： Disclosed are the ERK inhibitors of formula 1.0: and the pharmaceutically acceptable salts, esters and solvates thereof. Q is a piperidine or piperazine ring that can have a bridge or a fused ring. The piperidine ring can have a double bond in the ring. All other substitutents are as defined herein. Also disclosed are methods of treating cancer using the compounds of formula 1.0.
摘要翻译：公开了式1.0的ERK抑制剂及其药学上可接受的盐，酯和溶剂化物。 Q是可以具有桥或稠合环的哌啶或哌嗪环。哌啶环可以在环中具有双键。所有其他取代基如本文所定义。还公开了使用式1.0化合物治疗癌症的方法。

5. 发明授权

US08546404B2 Compounds that are ERK inhibitors 有权
标题翻译： ERK抑制剂的化合物
公开(公告)号：US08546404B2
公开(公告)日：2013-10-01
申请号：US11810282
申请日：2007-06-05
申请人： Alan B. Cooper , Yongqi Deng , Gerald W. Shipps, Jr. , Neng-Yang Shih , Hugh Y. Zhu , Robert Sun , Joseph M. Kelly , Ronald J. Doll , Yang Nan , Tong Wang , Jagdish A. Desai , James J-S Wang , Youhao Dong , Vincent S. Madison , Li Xiao , Alan W. Hruza , M. Arshad Siddiqui , Ahmed A. Samatar , Sunil Paliwal , Hon-Chung Tsui , Azim Alan Celebi , Yiji Wu , Sobhana Babu Boga , Abdul-Basit Alhassan , Xiaolei Gao , Liang Zhu , Mehul Patel
发明人： Alan B. Cooper , Yongqi Deng , Gerald W. Shipps, Jr. , Neng-Yang Shih , Hugh Y. Zhu , Robert Sun , Joseph M. Kelly , Ronald J. Doll , Yang Nan , Tong Wang , Jagdish A. Desai , James J-S Wang , Youhao Dong , Vincent S. Madison , Li Xiao , Alan W. Hruza , M. Arshad Siddiqui , Ahmed A. Samatar , Sunil Paliwal , Hon-Chung Tsui , Azim Alan Celebi , Yiji Wu , Sobhana Babu Boga , Abdul-Basit Alhassan , Xiaolei Gao , Liang Zhu , Mehul Patel
IPC分类号： A01N43/54 , C07D239/42 , C07D401/04
CPC分类号： C07D231/56 , C07D401/14 , C07D403/12 , C07D403/14 , C07D405/14 , C07D409/12 , C07D409/14 , C07D413/12 , C07D417/14
摘要： Disclosed are the ERK inhibitors of formula 1.0: and the pharmaceutically acceptable salts, esters and solvates thereof. Q is a piperidine or piperazine ring that can have a bridge or a fused ring. The piperidine ring can have a double bond in the ring. All other substitutents are as defined herein. Also disclosed are methods of treating cancer using the compounds of formula 1.0.
摘要翻译：公开了式1.0的ERK抑制剂及其药学上可接受的盐，酯和溶剂化物。 Q是可以具有桥或稠合环的哌啶或哌嗪环。哌啶环可以在环中具有双键。所有其他取代基如本文所定义。还公开了使用式1.0化合物治疗癌症的方法。

6. 发明申请

US20110038876A1 HETEROCYCLIC COMPOUNDS AND USE THEREOF AS ERK INHIBITORS 审中-公开
标题翻译：杂环化合物及其作为ERK抑制剂的用途
公开(公告)号：US20110038876A1
公开(公告)日：2011-02-17
申请号：US12601476
申请日：2008-06-17
申请人： Robert Sun , Alan B. Cooper , Yongqi Deng , Tong Wang , Yang Nan , Hugh Y. Zhu , Sobhana Babu Boga , Xiaolei Gao , Joseph M. Kelly , Sunil Paliwal , Hon-Chung Tsui , Ronald J. Doll , Neng-Yang Shih
发明人： Robert Sun , Alan B. Cooper , Yongqi Deng , Tong Wang , Yang Nan , Hugh Y. Zhu , Sobhana Babu Boga , Xiaolei Gao , Joseph M. Kelly , Sunil Paliwal , Hon-Chung Tsui , Ronald J. Doll , Neng-Yang Shih
IPC分类号： A61K31/519 , C07D487/04 , C07D487/08 , A61K31/496 , A61K39/395 , A61P35/00 , A61P35/02
CPC分类号： C07D487/04 , C07D519/00
摘要： Disclosed are the ERK inhibitors of formula 1.0: [Formula (1.0)] and the pharmaceutically acceptable salts, esters and solvates thereof. Q is a piperidine or piperazine ring that can have a bridge or a fused ring. The piperidine ring can have a double bond in the ring. All other substitutents are as defined herein. Also disclosed are methods of treating cancer using the compounds of formula 1.0.
摘要翻译：公开了式1.0的ERK抑制剂：[式（1.0）]及其药学上可接受的盐，酯和溶剂化物。 Q是可以具有桥或稠合环的哌啶或哌嗪环。哌啶环可以在环中具有双键。所有其他取代基如本文所定义。还公开了使用式1.0化合物治疗癌症的方法。

7. 发明申请

US20060111412A1 Substituted 5-oxo pyrazoles and [1,2,4]triazoles as antiviral agents 失效
标题翻译：取代的5-氧代吡唑和[1,2,4]三唑作为抗病毒剂
公开(公告)号：US20060111412A1
公开(公告)日：2006-05-25
申请号：US11259397
申请日：2005-10-26
申请人： Gerald Shipps , Tong Wang , Kristin Rosner , Patrick Curran , Alan Cooper , Viyyoor Girijavallabhan
发明人： Gerald Shipps , Tong Wang , Kristin Rosner , Patrick Curran , Alan Cooper , Viyyoor Girijavallabhan
IPC分类号： A61K31/4196 , A61K31/4152 , C07D249/12 , C07D231/08
CPC分类号： C07D231/20 , C07D231/22 , C07D401/12 , C07D403/04 , C07D409/12 , C07D417/12
摘要： The present invention provides compounds of formula I wherein X and R1-R7 are as defined herein. Compositions containing these compounds, and methods for inhibiting HCV RNA-dependent RNA polymerase and treating hepatitis C and related disorders using these compounds and compositions are also provided.
摘要翻译：本发明提供式I化合物，其中X和R 1 -R 7如本文所定义。还提供了含有这些化合物的组合物，以及用于抑制HCV RNA依赖性RNA聚合酶和使用这些化合物和组合物治疗丙型肝炎和相关病症的方法。

8. 发明授权

US07196111B2 Pyrazolo[1,5a]pyrimidine compounds as antiviral agents 失效
标题翻译：吡唑并[1,5a]嘧啶化合物作为抗病毒剂
公开(公告)号：US07196111B2
公开(公告)日：2007-03-27
申请号：US10452400
申请日：2003-06-02
申请人： Gerald W. Shipps , Kristin E. Rosner , Janet Popovici-Muller , Yongqi Deng , Tong Wang , Patrick J. Curran
发明人： Gerald W. Shipps , Kristin E. Rosner , Janet Popovici-Muller , Yongqi Deng , Tong Wang , Patrick J. Curran
IPC分类号： C07D231/00 , C07D231/54 , A61K31/415 , A01N43/56
CPC分类号： C07D487/04
摘要： The invention relates to the inhibition of hepatitis C virus (HCV) replication. In particular, embodiments of the invention provide compounds and methods for inhibiting HCV RNA-dependent RNA polymerase enzymatic activity. The invention also provides compositions and methods for the prophylaxis and treatment of HCV infection.
摘要翻译：本发明涉及丙型肝炎病毒（HCV）复制的抑制。特别地，本发明的实施方案提供了用于抑制HCV RNA依赖性RNA聚合酶酶活性的化合物和方法。本发明还提供了预防和治疗HCV感染的组合物和方法。

9. 发明授权

US09503191B2 GMP mapping method and apparatus for optical channel data unit 有权
标题翻译：用于光通道数据单元的GMP映射方法和装置
公开(公告)号：US09503191B2
公开(公告)日：2016-11-22
申请号：US14396958
申请日：2012-04-26
申请人： Shangqing Wu , Tong Wang , Yingfei Li , Zhangbin Lu
发明人： Shangqing Wu , Tong Wang , Yingfei Li , Zhangbin Lu
IPC分类号： H04J3/02 , H04B10/27 , H04J3/16 , H04J3/07
CPC分类号： H04B10/27 , H04J3/02 , H04J3/07 , H04J3/1652
摘要： The disclosure discloses a Generic Mapping Procedure (GMP) mapping method for an Optical channel Data Unit (ODU), including: caching low-level ODUk data to a memory according to the rate of low-level ODUk data stream; generating an adjustment byte in a mapping process and encoding the adjustment byte; generating read enable of the cached data by an algorithm according to the adjustment byte, reading the cached low-level ODUk data, and generating Optical channel Data Tributary Unit (ODTU) data according to the read data; and crossing a time slot of the ODTU data in multiple channels to that of a high-level ODU payload, and forming the data in the time slot of the high-level ODU payload and the encoded adjustment byte into a completed high-level ODU frame. The disclosure may further provide a GMP mapping apparatus for an ODU. According to a technical solution of the disclosure, the GMP mapping of the ODU can be implemented according to the dynamic change of a service rate.
摘要翻译：本公开公开了一种用于光信道数据单元（ODU）的通用映射过程（GMP）映射方法，包括：根据低级ODUk数据流的速率将低级ODUk数据缓存到存储器; 在映射过程中生成调整字节并对调整字节进行编码; 通过根据调整字节的算法生成缓存数据的读取使能，读取缓存的低级ODUk数据，以及根据读取的数据生成光信道数据支路单元（ODTU）数据; 并且将多个信道中的ODTU数据的时隙与高级ODU有效载荷的时隙交叉，并将高级ODU有效载荷和编码调整字节的时隙中的数据形成为完成的高级ODU帧。本公开还可以提供用于ODU的GMP映射设备。根据本公开的技术方案，ODU的GMP映射可以根据业务速率的动态变化来实现。

10. 发明授权

US08987468B2 Compounds, pharmaceutical compositions and methods of use of hydroxamic acid derivatives 有权
标题翻译：化合物，药物组合物和异羟肟酸衍生物的使用方法
公开(公告)号：US08987468B2
公开(公告)日：2015-03-24
申请号：US12865903
申请日：2009-02-03
申请人： Tong Wang , Stephen Gately
发明人： Tong Wang , Stephen Gately
IPC分类号： C07D235/00 , C07C239/00 , C07C259/00 , C07D235/16 , C07D403/04
CPC分类号： A61K31/506 , A61K31/4184 , A61K31/437 , A61K45/06 , C07D235/16 , C07D403/04
摘要： The invention encompasses a compound derived from hydroxamic acid that may be used to slow the expansion of cancer cells and thus is effective in the treatment of cancer. Generally, the disclosed compound includes a benzimidazole group coupled to a hydroxyamide of five or more unsubstituted carbon atoms and any pharmaceutically acceptable salts, solvates and chemically protected forms thereof. Also disclosed are pharmacological compositions including the compound and methods of using the compound to slow the expansion of cancer cells as well as methods of using the compound to treat cancer.
摘要翻译：本发明包括衍生自异羟肟酸的化合物，其可用于减缓癌细胞的扩增，因此有效治疗癌症。通常，所公开的化合物包括与五个或更多个未取代的碳原子的羟基酰胺偶联的苯并咪唑基团和其任何药学上可接受的盐，溶剂合物和化学保护形式。还公开了药物组合物，包括该化合物和使用该化合物减缓癌细胞扩增的方法以及使用该化合物治疗癌症的方法。

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式